Company Profile · Healthcare

Moderna Inc

MRNA · US
Exchange
US
Country
USA
IPO date
Dec 7, 2018
Employees
4,700
Current Price
$63.96
Live · Jun 18, 2026
Fair Buy
≤ $38
Margin-of-safety entry
Baillie Growth Score
44/100
Weak
Intrinsic Value · Three-Tier Range Current price $63.96 Live · Between the fair and optimistic ranges

Composite valuation range · conservative $20–$30 / fair $40–$55 / optimistic $70–$90. At $63.96, Between the fair and optimistic ranges.

At publication $47.19 (May 30, 2026)

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Market cap$24.52B
Revenue (TTM)$2.22B
EBITDA-$2.3B
Profit margin-143.55%
ROE-36.56%
Forward P/E23.04
PEG0
EPS-$8.14
52-week range$22.28 – $62.30
Analyst target$43.30
Analyst rating3.2 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.